Company intelligence / Profile preview

EG 427

Paris, Ile de France, Franceeg427.com ↗

Ownership: Private
Employees: ~50
Development stage: Phase 1

Overview

EG 427 has initiated a first-in-human clinical study with its lead gene therapy candidate, EG110A, targeting neurogenic detrusor overactivity. The company’s proprietary HERMES platform uses non-replicative HSV‑1 vectors to deliver durable and selective transgene expression to neural cells. Early preclinical data have shown positive safety and efficacy signals; the ongoing Phase 1b/2a trial will provide initial human safety data by mid‑2025. The company aims to address significant unmet needs in neuro-urology with potential expansion into broader neurological diseases.

Therapeutic areas: Women's HealthNeurologyUrology
Modalities: Gene therapy (non-replicative HSV-1 vector)DNA medicines
Industry: Biotech

Drug pipeline

3 assets

EG110A

2 more assets in the full pipeline.

Request access →

Partnerships

No major pharma partnerships disclosed as of May 2025; key investors include Andera Partners, Bpifrance/InnoBio funds, SCI Ventures

Beyond the preview

Go deeper on EG 427.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EG 427.

Explore the full profile